{"id":"https://openalex.org/W2593935970","doi":"https://doi.org/10.1182/blood.v128.22.930.930","title":"Nivolumab (Anti-PD1) Therapy for Relapsed/ Refractory Primary Central Nervous System Lymphoma and Primary Testicular Lymphoma","display_name":"Nivolumab (Anti-PD1) Therapy for Relapsed/ Refractory Primary Central Nervous System Lymphoma and Primary Testicular Lymphoma","publication_year":2016,"publication_date":"2016-12-02","ids":{"openalex":"https://openalex.org/W2593935970","doi":"https://doi.org/10.1182/blood.v128.22.930.930","mag":"2593935970"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v128.22.930.930","doi":"https://doi.org/10.1182/blood.v128.22.930.930","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.930.930","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018451725","display_name":"Lakshmi Nayak","orcid":"https://orcid.org/0000-0003-2725-8717","observed_orcids":["https://orcid.org/0000-0003-2725-8717"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lakshmi Nayak","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087754052","display_name":"FABIO MASSAITI IWAMOTO","orcid":"https://orcid.org/0000-0003-1397-9927","observed_orcids":["https://orcid.org/0000-0003-1397-9927"]},"institutions":[{"id":"https://openalex.org/I78577930","display_name":"Columbia University","ror":"https://ror.org/00hj8s172","country_code":"US","type":"education","lineage":["https://openalex.org/I78577930"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Fabio Iwamoto","raw_affiliation_strings":["Columbia University, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Columbia University, New York, NY","institution_ids":["https://openalex.org/I78577930"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085801543","display_name":"Ann Steward LaCasce","orcid":"https://orcid.org/0000-0001-7349-0176","observed_orcids":["https://orcid.org/0000-0001-7349-0176"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann S. LaCasce","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001968372","display_name":"Srinivasan Mukundan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Srinivasan Mukundan","raw_affiliation_strings":["Brigham and Women's Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital, Boston, MA","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013440190","display_name":"Margaretha G.M. Roemer","orcid":"https://orcid.org/0000-0003-0220-3496","observed_orcids":["https://orcid.org/0000-0003-0220-3496"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Margaretha G M Roemer","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074215180","display_name":"Bjoern Chapuy","orcid":"https://orcid.org/0000-0002-6485-8773","observed_orcids":["https://orcid.org/0000-0002-6485-8773","https://orcid.org/0000-0002-0886-9769"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bjoern Chapuy","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053410437","display_name":"Philippe A. Armand","orcid":"https://orcid.org/0000-0001-6098-1603","observed_orcids":["https://orcid.org/0000-0001-6098-1603"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philippe Armand","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","Division of Hematology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Division of Hematology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058975989","display_name":"Scott J. Rodig","orcid":"https://orcid.org/0000-0003-1761-9769","observed_orcids":["https://orcid.org/0000-0003-1761-9769"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott J. Rodig","raw_affiliation_strings":["Dana Farber, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber, Boston, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021363179","display_name":"Margaret Ann Shipp","orcid":"https://orcid.org/0000-0002-3949-6897","observed_orcids":["https://orcid.org/0000-0002-3949-6897"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Margaret A. Shipp","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5001968372","https://openalex.org/A5013440190","https://openalex.org/A5087754052"],"corresponding_institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I78577930"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.903,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.75402743,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":97,"max":98},"biblio":{"volume":"128","issue":"22","first_page":"930","last_page":"930"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.006300000008195639,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9179999828338623},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.9240000247955322},{"id":"https://openalex.org/keywords/primary-central-nervous-system-lymphoma","display_name":"primary central nervous system lymphoma","score":0.9710000157356262},{"id":"https://openalex.org/keywords/primary-testicular-lymphoma","display_name":"primary testicular lymphoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.9660000205039978},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.6980000138282776},{"id":"https://openalex.org/keywords/pd-l2","display_name":"PD-L2","score":0.9890000224113464},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7319999933242798},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.8069999814033508},{"id":"https://openalex.org/keywords/high-dose-methotrexate","display_name":"high-dose methotrexate","score":0.7070000171661377},{"id":"https://openalex.org/keywords/r-chop","display_name":"R-CHOP","score":0.7200000286102295},{"id":"https://openalex.org/keywords/autologous-stem-cell-transplantation","display_name":"autologous stem cell transplantation","score":0.6880000233650208},{"id":"https://openalex.org/keywords/whole-brain-radiation","display_name":"whole brain radiation","score":0.6449999809265137}],"concepts":[{"id":"https://openalex.org/C2781173314","wikidata":"https://www.wikidata.org/wiki/Q3246818","display_name":"Primary central nervous system lymphoma","level":3,"score":0.7130213975906372},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6926393508911133},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.6144412159919739},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.5970702171325684},{"id":"https://openalex.org/C2779725641","wikidata":"https://www.wikidata.org/wiki/Q1076228","display_name":"CHOP","level":3,"score":0.5400487184524536},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.5122177004814148},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5063368082046509},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5025653839111328},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48495912551879883},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.42632555961608887},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.39403676986694336},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.32362139225006104}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v128.22.930.930","doi":"https://doi.org/10.1182/blood.v128.22.930.930","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.930.930","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2600581432","https://openalex.org/W3096290750","https://openalex.org/W2621993514","https://openalex.org/W2610859439","https://openalex.org/W2556719006","https://openalex.org/W2949195371","https://openalex.org/W2622023090","https://openalex.org/W4310163517","https://openalex.org/W3040140433","https://openalex.org/W4380084803"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Primary":[2],"central":[3],"nervous":[4],"system":[5],"lymphoma":[6,11,235],"(PCNSL)":[7],"and":[8,15,24,44,78,95,124,129,150,155,158,183,211,215,247,250,259,274,309,314,333,349,360,387,400,419,485,495,528,531,542,558,561],"primary":[9,84,320,526],"testicular":[10,114],"(PTL)":[12],"are":[13,42,49,118,168,493],"rare":[14],"aggressive":[16],"extranodal":[17],"non-Hodgkin":[18],"lymphomas":[19,227],"with":[20,32,59,70,90,103,110,122,170,228,256,261,288,307,312,328,363,413,425,437,533],"shared":[21],"molecular":[22,540],"features":[23],"a":[25,196,264,289,486,547],"poor":[26],"prognosis.":[27],"PCNSL":[28,71,126,154,246,258,308,530,560],"is":[29,88,511,523,565],"currently":[30],"treated":[31,89,253,327,362],"high-dose":[33,57,346],"methotrexate":[34],"(HD-MTX)":[35],"based":[36,343],"induction":[37,107],"chemotherapy.":[38],"Younger":[39],"patients":[40,69,82,102,121,133,255,300,306,324,356,406,467,492,502,563],"who":[41,468],"healthy":[43],"eligible":[45],"for":[46,51,120],"consolidation":[47],"treatment":[48,412],"considered":[50],"whole":[52],"brain":[53],"radiation":[54],"(WBRT)":[55],"or":[56,112,127,191,279,479],"chemotherapy":[58,351],"autologous":[60],"stem-cell":[61],"transplant":[62],"(ASCT).":[63],"Despite":[64],"this,":[65],"nearly":[66],"50%":[67,100],"of":[68,76,81,101,132,136,173,186,199,222,242,295,330,398,434,454,474,482,554],"relapse":[72,427],"within":[73],"2":[74,369,401,550],"years":[75,287],"diagnosis":[77],"one":[79],"third":[80],"have":[83],"refractory":[85,125,321,527,559],"disease.":[86,138],"PTL":[87,104,156,260,313,429,532,562],"rituximab,":[91],"cyclophosphamide,":[92],"doxorubicin,":[93],"vincristine":[94],"prednisone":[96],"(R-CHOP).":[97],"However,":[98],"almost":[99],"progress":[105],"after":[106],"treatment,":[108],"frequently":[109],"CNS":[111,315,426,435,534],"contralateral":[113],"involvement.":[115],"Treatment":[116],"options":[117],"limited":[119],"recurrent":[123,303,557],"PTL,":[128],"the":[130,174,240,472],"majority":[131],"ultimately":[134],"die":[135],"their":[137],"We":[139,252],"recently":[140],"identified":[141],"frequent":[142],"9p24.1/":[143],"PD-L1(CD274)/":[144],"PD-L2":[145,192],"(PDCD1LG2)":[146],"copy":[147],"number":[148,453],"alterations":[149,167,230],"additional":[151],"translocations":[152],"in":[153,225,245,389,489,525,556],"(Chapuy":[157],"Roemer":[159],"et":[160],"al":[161],"Blood":[162],"2016;":[163],"127:869-81).":[164],"These":[165],"genetic":[166],"associated":[169],"increased":[171],"expression":[172],"programmed":[175],"cell":[176],"death":[177],"protein":[178],"1":[179,310,317,372,393,420],"(PD-1)":[180],"ligands,":[181],"PD-L1":[182,190,278],"PD-L2.":[184,280],"Activation":[185],"PD-1":[187,223,273],"signaling":[188],"by":[189,203,277,353],"binding":[193,276],"leads":[194],"to":[195,238,411,457,504,567],"reversible":[197],"state":[198],"T-cell":[200,205,209],"\"exhaustion\"":[201],"characterized":[202],"decreased":[204],"receptor":[206],"signaling,":[207],"reduced":[208],"proliferation":[210],"survival,":[212],"perturbed":[213],"metabolism":[214],"altered":[216],"transcription":[217],"factor":[218],"expression.":[219],"The":[220,423,451,465,507],"activity":[221],"blockade":[224],"other":[226,336],"9p24.1":[229],"such":[231],"as":[232],"classical":[233],"Hodgkin's":[234],"prompted":[236],"us":[237],"test":[239],"efficacy":[241],"this":[243,499],"approach":[244],"PTL.":[248],"Patients":[249],"Methods:":[251],"5":[254],"recurrent/refractory":[257],"off-label":[262],"Nivolumab,":[263],"humanized":[265],"IgG4":[266],"monoclonal":[267],"antibody":[268],"checkpoint":[269],"inhibitor":[270],"that":[271,441,521],"targets":[272],"blocks":[275],"Median":[281],"age":[282],"was":[283,461],"64":[284],"(range,":[285,463,513],"54-85)":[286],"median":[290,452,508],"Karnofsky":[291],"Performance":[292],"Score":[293],"(KPS)":[294],"70":[296],"(40-80)":[297],"%.":[298],"Four":[299,501],"had":[301,319,325,334,407,430,477],"multiply":[302],"disease":[304,440],"(3":[305],"patient":[311,318,373,394,424],"relapse);":[316],"PCNSL.":[322],"All":[323,355,405,444,491],"been":[326],"standard":[329],"care":[331],"treatments":[332,456],"no":[335],"available":[337],"options.":[338],"Prior":[339],"therapies":[340],"included":[341],"HD-MTX":[342],"chemotherapy,":[344],"pemetrexed,":[345],"cytarabine,":[347],"WBRT":[348],"thiotepa-based":[350],"followed":[352],"ASCT.":[354],"signed":[357],"informed":[358],"consent":[359],"were":[361,384,446,469],"nivolumab":[364,381,455,475,522,555],"at":[365,448,471,498],"3mg/kg":[366],"intravenously":[367],"every":[368],"weeks.":[370,391],"Only":[371],"received":[374,395,403],"corticosteroids":[375],"(dexamethasone":[376],"2mg":[377],"daily)":[378],"during":[379],"initial":[380],"treatment;":[382],"steroids":[383],"rapidly":[385],"tapered":[386],"discontinued":[388],"4":[390,416,466],"Additionally,":[392],"3":[396,462],"doses":[397],"rituximab":[399],"others":[402],"WBRT.":[404],"objective":[408,458],"radiographic":[409,432,459],"responses":[410,418,445],"nivolumab,":[414],"including":[415],"complete":[417,431,478],"partial":[421],"response.":[422],"from":[428],"resolution":[433,481],"abnormalities":[436],"persistent":[438],"intraocular":[439],"required":[442],"vitrectomy.":[443],"confirmed":[447],"repeat":[449],"restaging.":[450],"response":[460],"2-4).":[464],"symptomatic":[470],"initiation":[473],"therapy":[476],"near-complete":[480],"neurologic":[483],"signs/symptoms":[484],"marked":[487],"improvement":[488],"KPS.":[490],"alive":[494],"remain":[496],"progression-free":[497,509],"time.":[500],"continue":[503],"receive":[505],"treatment.":[506],"survival":[510],"9":[512],"7-11)":[514],"months.":[515],"Conclusion:":[516],"Our":[517],"pilot":[518,544],"series":[519],"indicates":[520],"active":[524],"relapsed/refractory":[529],"relapse.":[535],"Based":[536],"on":[537],"our":[538],"preclinical":[539],"data":[541],"these":[543],"clinical":[545],"results,":[546],"multi-institutional":[548],"phase":[549],"open-label,":[551],"single-arm":[552],"trial":[553],"(CA209-647)":[564],"scheduled":[566],"open":[568],"shortly.":[569],"Disclosures":[570],"LaCasce:":[571],"Forty":[572],"Seven:":[573],"Consultancy;":[574,580],"Seattle":[575],"Genetics:":[576],"Consultancy.":[577],"Armand:Infinity":[578],"Pharmaceuticals:":[579],"Merck:":[581],"Consultancy,":[582,597,615],"Research":[583,586,589,593,598,601,616],"Funding;":[584,587,590,594,602],"Pfizer:":[585],"Roche:":[588],"Sequenta":[591],"Inc:":[592],"Bristol-Myers":[595,613],"Squibb:":[596,614],"Funding.":[599,617],"Shipp:Bayer:":[600],"Merck,":[603],"Gilead,":[604],"Takeda:":[605],"Other:":[606],"Scientific":[607],"Advisory":[608],"Board;":[609],"Cell":[610],"Signaling:":[611],"Honoraria;":[612]},"counts_by_year":[{"year":2017,"cited_by_count":4}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2017-03-16T00:00:00"}